Oral Danuglipron Shows Competent Efficacy and Safety Profile To Semaglutide Injection

      A phase 2b, double-blind, placebo-controlled trial demonstrated that oral danuglipron can be as effective as other GLP-1 agonists in reducing weight and controlling glycemic levels. During the analysis of the drug's potential benefits, researchers identified that danuglipron doses of 80 mg or more taken twice daily resulted in consistent weight reduction. Conversely, the use of lower doses of danuglipron (≤40 mg twice daily) did not have a significant impact on body weight. The weight loss observed with higher doses of danuglipron is comparable to that observed in phase 2 data for oral semaglutide and injectable GLP-1R agonists when administered for similar durations, as reported in JAMA. Notably, danuglipron exhibited a safety and efficacy profile similar to that of peptidic GLP-1R agonists but without fasting restrictions.